XML 26 R13.htm IDEA: XBRL DOCUMENT
v3.23.2

LEASES | 6 Months Ended
--- | ---
Jun. 30, 2023
Leases [Abstract] |
LEASES | LEASES The Company leases all of its facilities, including its EXPAREL and iovera° handpiece manufacturing facility at its Science Center Campus in San Diego, California. The Company also has two embedded leases with Thermo Fisher Scientific Pharma Services for the use of their manufacturing facility in Swindon, England for the production of EXPAREL and ZILRETTA. A portion of the associated monthly base fees has been allocated to the lease components based on a relative fair value basis. Since July 2022 and February 2023, the Company has been recognizing sublease income for laboratory space leased in Woburn, Massachusetts and a portion of office space leased in Burlington, Massachusetts, respectively, from leases that were assumed as part of the Flexion Acquisition. Subsequent to June 30, 2023, the Company partially exited its Burlington, Massachusetts office space lease that had been assumed as part of the Flexion Acquisition at a one-time termination fee of $0.8 million, which released its obligation of $1.6 million in future cash payments for the respective proportion of square footage exited. The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease expense, net is as follows (in thousands):
|  | Three Months Ended |  | Six Months Ended
|  | June 30, |  | June 30,
|  | 2023 |  | 2022 |  | 2023 |  | 2022
Fixed lease costs |  | $ | 3,631 |  |  | $ | 3,542 |  |  | $ | 7,259 |  |  | $ | 7,069 |
Variable lease costs |  | 378 |  |  | 508 |  |  | 945 |  |  | 980 |
Sublease income |  | (169) |  |  | — |  |  | (322) |  |  | — |
Total |  | $ | 3,840 |  |  | $ | 4,050 |  |  | $ | 7,882 |  |  | $ | 8,049 |
Supplemental cash flow information related to operating leases is as follows (in thousands):
|  | Six Months Ended
|  | June 30,
|  | 2023 |  | 2022
Cash paid for operating lease liabilities, net of lease incentives |  | $ | 7,325 |  |  | $ | 6,637 |
The Company has elected to net the amortization of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows. The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:
|  | June 30,
|  | 2023 |  | 2022
Weighted average remaining lease term |  | 6.39 years |  | 7.33 years
Weighted average discount rate |  | 7.03 | % |  | 6.95 | %
Maturities of the Company’s operating lease liabilities are as follows (in thousands):
Year |  | Aggregate Minimum Payments Due
2023 (remaining six months) |  | $ | 6,925 |
2024 |  | 13,928 |
2025 |  | 13,078 |
2026 |  | 12,814 |
2027 |  | 12,587 |
Thereafter |  | 27,350 |
Total future lease payments |  | 86,682 |
Less: imputed interest |  | (17,655) |
Total operating lease liabilities |  | $ | 69,027 |

X
- References No definition available. + Details
Name: | us-gaap_LeasesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-20/tableOfContent + Details
Name: | us-gaap_LesseeOperatingLeasesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration